OCUMENSION-B (01477): Completion of patient enrollment for the Phase III clinical trial of OT-211.

OCUMENSION-B (01477) has announced that the Phase III clinical trial of OT-211 (TRYPTYR Acarbose eye drops) in the People's Republic of China has recently completed the enrollment of a total of 398 patients. OT-211 (TRYPTYR Acarbose eye drops) is a 0.003% concentration eye drop formulation and is the first TRPM8 agonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of Dry Eye Disease (DED). In March 2026, the enrollment of the first patient in the Phase III clinical trial of OT-211 in China was completed, marking a significant milestone in the clinical development of OT-211 in China and reflecting the Group's commitment to advancing innovative therapies for DED patients. Alcon Inc. (collectively referred to with its subsidiaries as the "Alcon Group") is a leader in the global ophthalmic care field, covering both surgical and vision care sectors. It has developed a 0.003% concentration eye drop formulation of AR-15512 and completed a Phase IIb and three Phase III clinical trials. OT-211 received FDA approval for the treatment of DED signs and symptoms on May 28, 2025. Following a strategic partnership formed in October 2024 with the Alcon Group, the Group has obtained an exclusive license from the Alcon Group to develop, manufacture, outsource manufacture, import, export, and sell OT-211 in mainland China. The successful enrollment of OT-211 marks a strong collaboration and binding between the company and the Alcon Group in the field of new drug development, laying the foundation for future joint exploration and development of new drugs.